( MILAN Italy and DAYTON Ohio June 08...)Eurand to Present Zentase Phase III Data,Health

MILAN, Italy, and DAYTON, Ohio, June 08, 2007 /PRNewswire-FirstCall/ --Eurand to present data on Zentase at European Cystic Fibrosis Society Annual Meeting. .

-- Exocrine pancreatic insufficiency (EPI) is a deficiency of digestive

enzymes normally produced by the pancreas that can result from a number

of diseases, including cystic fibrosis, chronic pancreatitis, and

pancreatic cancer


-- EPI results in poor digestion and reduced absorption of nutrients

which, if untreated, can lead to impaired growth in children, impaired

immune response and shortened life expectancy


-- Treatment with pancreatic replacement products replaces enzymes lost

through this disease. Other than enzyme replacement, no known

alternative therapy for the loss of digestive enzymes is currently

available


-- Eurand completed two phase III clinical trials on its lead product

candidate, Zentase(TM), for the treatment of EPI


-- Eurand expects to initiate a rolling submission of its new drug

application (NDA) with the US Food and Drug Administration (FDA) for

Zentase for the treatment of EPI in the 2nd quarter of this year


-- Posters 243-246 will be presented on June 15th between 1:30-2:30pm:


1. Zentase, a New Pancreatic Enzyme Product (PEP), Is Safe and

Effective in Cystic Fibrosis (CF) Patients with Exocrine Pancreatic

Insufficiency (EPI)

2. Zentase, a New Pancreatic Enzyme Product (PEP), in Young Cystic

Fibrosis (CF) Patients with Exocrine Pancreatic Insufficiency (EPI)
<
'"/>




Page: 1 2 3
Related medicine technology :

1. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
2. Eurand Announces Positive Phase III Clinical Study Results
3. The Past, Present and Future of HLA Typing
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference